Article Per Year (5 Year)
p-Index From 2020 - 2025
0.444
P-Index
This Author published in this journals
All Journal Pharmacology and Clinical Pharmacy Research
Laxminarayana Kamath
Bangalore Medical College and Research Institute
Medicine & Pharmacology

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search
Journal : Pharmacology and Clinical Pharmacy Research

 1 
A Comparative Study to Evaluate Efficacy and Safety of Daily Dosing versus Alternate-Day Atorvastatin Therapy in Patients with Dyslipidemia Allen J. Rodrigues; Syed S. Farookh; Laxminarayana Kamath; Raveendra K.R
Pharmacology and Clinical Pharmacy Research Vol 6, No 2 (2021)
Publisher : Universitas Padjadjaran, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.15416/pcpr.v6i2.32412

Abstract

  Dyslipidemia is a well-recognized risk factor for the development of diseases associated with atherosclerosis, including coronary artery disease and stroke. Statins are the first choice hypolipidemic drug which are the most effective and best tolerated agents for treating dyslipidemia. Atorvastatin confers an HMG-CoA reductase inhibition up to 20-30 hours which makes it even effective on the next day. The present study is randomized open labeled study done at Victoria Hospital - Bangalore to compare efficacy and safety of daily dosing versus alternate-day atorvastatin therapy in patients with dyslipidemia. A total of 86 patients with dyslipidemia were randomized into 2 groups. Group A received 10 mg of atorvastatin daily (DS) and group B received 10 mg of atorvastatin on alternate day (AS) for six weeks. Among the 86 patients included in the study, mean age of the participants in the AS group was 53.12 ± 10.32 whereas that in the DS group was 52.26 ± 11.13. LDL-C decreased by 25.3% versus 22.4% (CI 0.95, P = 0.35) on daily and alternate-day dosing, respectively. Also 12.5% versus 15% (CI 0.95, P= 0.83) improvement was seen with HDL-C. Both dosage regimens provided reductions in total cholesterol (20.7% versus 20.2%) and triglyceride (20.7% versus 21.2%). There was no statistically significant difference in reduction in lipid parameters between two groups. Adverse effects were found less occurred in alternate day therapy than daily therapy. Gastrointestinal disturbances and myalgia were most commonly reported in both groups. Hence this study concludes alternate-day atorvastatin is as effective as daily atorvastatin in dyslipidemia. 
Study to Evaluate the Efficacy and Safety of Topical Lipid-based Amphotericin B Gel 0.1% in Patients with Cutaneous Mycosis Resistant to Conventional Therapy Mamatha Kamarthi; Raghav M V; Laxminarayana Kamath; Revathi T N
Pharmacology and Clinical Pharmacy Research Vol 7, No 3 (2022)
Publisher : Universitas Padjadjaran, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.15416/pcpr.v7i3.38892

Abstract

The last few years have seen a significant rise in the incidence of cutaneous mycosis infections resistant to conventional therapy. Topical nanostructured lipid formulations of Amphotericin B have emerged as a novel system to tackle this menace. The present study is an open-label, single-arm, prospective study to analyze the efficacy and safety of topical nanostructured lipid-based Amphotericin B gel in treating patients attending Dermatology OPD, Victoria hospital, with cutaneous mycosis resistant to conventional therapy. Thirty patients diagnosed with tinea corporis/cruris resistant to conventional therapy were included in the study.  Patients were advised to apply amphotericin B gel 0.1% on the affected area twice daily for four weeks. Outcome parameters like pruritus, erythema, vesicles, desquamation, and KOH mount were noted weekly for the assessment of efficacy and safety.  One-way ANOVA was used for statistical analysis. After treatment with Amphotericin B gel, patients showed a statistically significant reduction in pruritus, erythema, vesicles, and desquamation from baseline across time towards the end of 4 weeks (p<0.05).  Also, the Mean total score of all symptoms, which was 8.3±3.1 at baseline, was reduced to 0.9±0.7 at the end of the 4th week (p<0.05). All the patients treated were mycologically negative for KOH mount at the end of the study period. No serious adverse drug reactions were reported to treatment. To conclude, topical nanostructured lipid-based amphotericin B gel in patients with cutaneous mycosis resistant to conventional treatment was efficacious and safe.
Co-Authors Allen J. Rodrigues Mamatha Kamarthi Raghav M V Raveendra K.R Revathi T N Syed S. Farookh